VERONA PHARMA PLC - AM

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs

15 авг 2022 13:05:00 Источник Nasdaq GlobeNewswire

Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering

10 авг 2022 17:22:20 Источник Nasdaq GlobeNewswire

Verona Pharma plc Announces Proposed Underwritten Public Offering

09 авг 2022 13:16:44 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update

09 авг 2022 00:01:03 Источник Nasdaq GlobeNewswire

Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD

08 авг 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD

08 авг 2022 13:30:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update

28 июл 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

08 июн 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Host KOL Event on June 16, 2022

05 июн 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present at Jefferies Healthcare Conference

24 май 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022

08 май 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Announces May 2022 Investor Conference Participation

03 май 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update

02 май 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update

18 апр 2022 23:00:00 Источник Nasdaq GlobeNewswire

James Brady Joins Verona Pharma as Non-Executive Director

14 мар 2022 00:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

02 мар 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

16 фев 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

23 янв 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

04 янв 2022 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference

03 янв 2022 23:00:00 Источник Nasdaq GlobeNewswire